As part of our AMR strategy, we have partnered with GARDP on the Global Neonatal Sepsis Observational Study (NeoOBS), which was launched in July 2018. NeoOBS is a in collaboration between GARDP, St George’s University of London, Penta, University of Antwerp, MRC Clinical Trial Unit at University College London and 19 hospitals mainly in limited-resource settings.
The overarching goal of this collaboration is to develop new and improved treatment regimens for the management of neonatal sepsis in settings with high prevalence of multidrug-resistant and extensively drug-resistant pathogens.
The primary objective of NeoOBS was to assess mortality rates of hospitalised infants being treated with significant sepsis. Secondary objectives included describing clinical presentation and recovery, sepsis management and microbiological epidemiology. This involved the collection of routine clinical, laboratory and antimicrobial therapy data from approximately 3000 neonates less than 60 days old with clinically diagnosed sepsis. Patients were followed for 28 days.
This global multi-centre prospective study has completed recruitment in February 2020 with each site having recruited up to 200 neonates. Data from the study will be used to inform the design of future antibiotic treatment trials for neonatal sepsis.
To know more about the programme, read:
More details on specific activities can be found on the GARDP website.